PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology ... poster presentations at the upcoming 2025 American Association for Cancer ...

--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology ... of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting ...

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentations have concluded.